FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET By Ogkologos - April 18, 2025 622 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Re-Thinking Community December 10, 2021 Evaluation of Pemigatinib Efficacy in FGFR-Altered Advanced Solid Tumours Led to... May 17, 2024 FDA Approves Cemiplimab-rwlc in Combination with Platinum-Based Chemotherapy for Advanced NSCLC November 25, 2022 How My Navy Career Helped Shape My Positive Attitude During My... December 16, 2020 Load more HOT NEWS New on NCI’s Websites for October 2019 ESMO Issues First Recommendations on Using Next-Generation Sequencing for Advanced Cancers... Grandma Saves Her Money To Put Up A Billboard For Everyone... The American Society of Clinical Oncology and the American Cancer Society:...
